Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Abroad (travel likely)RecruitingPHASE2
Conditions
Acute Myeloid Leukemia · Blasts 20-30 Percent of Bone Marrow Nucleated Cells · Chronic Myelomonocytic Leukemia · IDH2 Gene Mutation · Myelodysplastic Syndrome With Excess Blasts · Recurrent High Risk Myelodysplastic Syndrome · Refractory High Risk Myelodysplastic Syndrome
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
Cleveland Clinic Foundation, Cleveland, Ohio, United States
M D Anderson Cancer Center, Houston, Texas, United States
Contact: Principal Investigator (Courtney DiNardo)
Study leads
Courtney DiNardo
Principal Investigator
M.D. Anderson Cancer Center